GIRK2 splice variants and neuronal G protein-gated K channels: implications for channel function and behavior.
- Authors
- Marron Fernandez de Velasco, Ezequiel; Zhang, Lei; N Vo, Baovi; Tipps, Megan; Farris, Shannon; Xia, Zhilian; Anderson, Allison; Carlblom, Nicholas; Weaver, C David; Dudek, Serena M; Wickman, Kevin
- Year
- 2017
- Journal
- Scientific reports
- PMID
- 28487514
- DOI
- 10.1038/s41598-017-01820-2
- PMCID
- PMC5431628
Many neurotransmitters directly inhibit neurons by activating G protein-gated inwardly rectifying K (GIRK) channels, thereby moderating the influence of excitatory input on neuronal excitability. While most neuronal GIRK channels are formed by GIRK1 and GIRK2 subunits, distinct GIRK2 isoforms generated by alternative splicing have been identified. Here, we compared the trafficking and function of two isoforms (GIRK2a and GIRK2c) expressed individually in hippocampal pyramidal neurons lacking GIRK2. GIRK2a and GIRK2c supported comparable somato-dendritic GIRK currents in Girk2 pyramidal neurons, although GIRK2c achieved a more uniform subcellular distribution in pyramidal neurons and supported inhibitory postsynaptic currents in distal dendrites better than GIRK2a. While over-expression of either isoform in dorsal CA1 pyramidal neurons restored contextual fear learning in a conditional Girk2 mouse line, GIRK2a also enhanced cue fear learning. Collectively, these data indicate that GIRK2 isoform balance within a neuron can impact the processing of afferent inhibitory input and associated behavior.
Functional comparison of GIRK2a and GIRK2c in HEK cells. (A) Whole-cell currents (Vhold = β70 mV) evoked by baclofen (100 ΞΌM) in HEK cells expressing GABABR, GIRK1, and either GIRK2a (red) or GIRK2c (blue). No current was evoked by baclofen in cells expressing only GABABR (control, black). Scale: 500 pA/10 s. (B) Summary of baclofen-induced, steady-state current densities (Ibaclofen, pA/pF) in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (t 19 = 1.1, P = 0.29; n = 10β11/group). Individual data points are represented as small squares overlapping the relevant bar in the plot. (C,D) Activation (t 19 = 1.5, P = 0.16) and deactivation (t 16 = 0.4, P = 0.72) kinetics for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (n = 9β11/group). (E) Representative concentration-response experiment for a HEK cell expressing GABABR and GIRK1/GIRK2c. Scale: 500 pA/10 s. (F,G) Summary of concentration-response experiments for baclofen-induced currents in HEK cells expressing GIRK1/GIRK2a or GIRK1/GIRK2c (t 17 = 1.0, P = 0.32; n = 9β10/group). Currents were normalized to the response evoked by 100 ΞΌM baclofen in each experiment.
GIRK2 expression in the mouse hippocampus. (A) Girk2a and Girk2c mRNA levels as assessed by RNA-Seq in CA1 cell body and neuropil samples, taken from 3 adult mice. Main effects of isoform (F1,8 = 14.3, P < 0.01) and compartment (F1,8 = 27.1, P < 0.001) were observed, but there was no interaction between isoform and compartment (F1,8 = 0.07, P = 0.80). Symbols: *P < 0.05 vs. GIRK2a (within compartment); +,++ P < 0.05 and 0.01, respectively, vs. cell body (within isoform). (B) Representative GIRK2 immunoblots (from 3 independent experiments) of adult hippocampus and neonatal hippocampal culture (10β12 DIV) from wild-type (WT) and Girk2 β/β mice, probed with pan-GIRK2 or GIRK2c antibodies (upper blots), as well as a Ξ²-actin antibody (lower blots). (C,D) Representative images showing GIRK2 immunolabeling (as revealed with the pan-GIRK2 antibody) in cultured hippocampal neurons from wild-type (C) and Girk2 β/β (D) mice. Neurons were co-stained with a MAP2 antibody to highlight neuronal morphology and dendritic processes. Scale bar: 50 microns.
Subcellular distribution of GIRK2a and GIRK2c in Girk2 β/β pyramidal neurons. (A,B) Representative images showing GIRK2 (red) and MAP2 (green) immunolabeling, and their overlay, in Girk2 β/β hippocampal pyramidal neurons expressing either GIRK2a (A) or GIRK2c (B). Scale bars: 50 microns. The insets highlight different densities of GIRK2a and GIRK2c puncta along proximal/primary (Ai,Bi) and distal/secondary (Aii,Bii) dendritic segments. Scale bars: 5 microns. (C) Quantification of GIRK2a and GIRK2c labeling in dendrites from infected Girk2 β/β pyramidal neurons. GIRK2 fluorescence intensity was measured in 2β3 primary (t 27 = 1.4, P = 0.17), secondary (t 29 = 2.1, *P < 0.05), and tertiary (t 27 = 5.2, ***P < 0.001) dendritic segments from 5 different neurons expressing each subunit. Fluorescence intensity is expressed as arbitrary units (AU) normalized to segment length. Only GIRK2 labeling that overlapped directly with the dendritic segment (identified by MAP2 labeling) was quantified in this analysis.
Overlap of GIRK2a and GIRK2c with PSD-95 in pyramidal neurons. (A,B) Representative images showing GIRK2 (red) and PSD-95 (green) immunolabeling, and their overlay, in a Girk2 β/β hippocampal pyramidal neuron expressing GIRK2a (A) or GIRK2c (B). Scale bars: 50 microns. The inset (Bi) highlights the limited overlap between PSD-95 and GIRK2, as demonstrated with GIRK2c. Scale bars: 20 microns. (C) Quantification of overlap between PSD-95 and GIRK2a or GIRK2c, under control conditions and following morphine treatment (n = 8 per isoform and treatment condition). Main effects of isoform (F1,28 = 9.2, P < 0.01) and treatment (F1,28 = 22.1, P < 0.001) were observed, but there was no interaction between isoform and treatment (F1,28 = 0.3, P = 0.60). Symbols: *P < 0.05 vs. GIRK2a (within treatment); +,++ P < 0.05 and 0.01, respectively, vs. control (within isoform).
GPCR-GIRK currents in Girk2 β/β pyramidal neurons expressing GIRK2a or GIRK2c. (A) Whole-cell currents (Vhold = β70 mV) evoked by baclofen (100 ΞΌM) in a wild-type pyramidal neuron expressing EGFP (WT, black), as well as Girk2 β/β pyramidal neurons expressing EGFP (Girk2 β/β, gray), GIRK2a (red), or GIRK2c (blue). Scale: 1 nA/5 s. (B) Summary of baclofen-induced, steady-state current densities (pA/pF) in wild-type control and Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (F3,53 = 44.8, P < 0.001; n = 11β16/group). Symbols: ***P < 0.001 vs. WT. (C,D) Summary of activation (C; F2,35 = 19.2, P < 0.001) and deactivation (D) F2,33 = 2.76, P = 0.08) kinetics for baclofen-induced currents in infected wild-type and Girk2 β/β pyramidal neurons. Symbols: ***P < 0.001 vs. WT (n = 11β15 per group). (E) EC50 values for baclofen-induced currents in infected wild-type and Girk2 β/β pyramidal neurons expressing GIRK2a or GIRK2c (F2,17 = 8.84, P < 0.01; n = 6β8/group). Symbols: *,**P < 0.05 and 0.01, respectively, vs. WT. (F) Whole-cell currents evoked by adenosine (10 ΞΌM) in a wild-type pyramidal neuron expressing EGFP, as well as Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (Vhold = β70 mV). Scale: 500 pA/5 s. (G) Summary of adenosine-induced, steady-state current densities (Iadenosine, pA/pF) in wild-type control and Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (F3,36 = 32.1, P < 0.001; n = 9β13/group). Symbols: ***P < 0.001 vs. WT. (H) Whole-cell currents evoked by 8-OH-DPAT (10 ΞΌM) in a wild-type pyramidal neuron expressing EGFP, as well as Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (Vhold = β70 mV). As currents evoked by 8-OH-DPAT persisted following bath washout, the 5HT1AR-selective antagonist WAY100635 (WAY, 2 ΞΌM) was used to demonstrate reversibility of the 8-OH-DAT response. Scale: 500 pA/5 s. (I) Summary of 8-OH-DPAT-induced, steady-state current densities (I8-OH-DPAT, pA/pF) in wild-type control and Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (F3,30 = 7.92, P < 0.001; n = 5β11/group). Symbols: *P < 0.05 vs. WT. (J) Summary of current densities (pA/pF) evoked by 10 ΞΌM ML297 (IML297) in wild-type control and Girk2 β/β pyramidal neurons expressing EGFP, GIRK2a, or GIRK2c (F2,12 = 2.0, P = 0.16; n = 5β8/group).
Synaptic GIRK currents in Girk2 β/β neurons expressing GIRK2a and GIRK2c. (A) Image showing EGFP expression in the CA1 region of an organotypic hippocampal slice, taken 7 d after infection with AAV8-hSyn-GIRK2a-IRES-EGFP. The dotted white line highlights key features of slice morphology. Scale bar: 500 microns (inset: 50 microns). (B) Summary of peak baclofen-induced somatodendritic current amplitudes (Ibaclofen) in dorsal CA1 pyramidal neurons, measured 7 d after CA1 infusion of control virus (con) to wild-type (WT) organotypic slices, or GIRK2 expression viruses (2a, 2c) to Girk2 β/β organotypic slices (F2,17 = 1.2, P < 0.01; n = 6β7/group). Symbols *,**P < 0.05 and 0.01, respectively, vs. WT. (C) Slow IPSCs evoked via stimulation of proximal (Schaffer collateral/SC) or distal (perforant path, PP) dendritic fields, in wild-type and Girk2 β/β CA1 pyramidal neurons expressing EGFP, as well as Girk2 β/β CA1 pyramidal neurons expressing GIRK2a or GIRK2c. The stimulus artifact and residual GABAAR-dependent responses were removed for clarity, and the triangles below the traces denote stimulation times. Scale: 100 pA/1 s. (D) Summary plot comparing the ratios of slow IPSC maximal amplitudes evoked by SC and PP stimulation in wild-type CA1 pyramidal neurons expressing EGFP, as well as Girk2 β/β CA1 pyramidal neurons expressing GIRK2a or GIRK2c (F2,37 = 51.9; P < 0.001; n = 6β8/group). Maximal responses evoked by stimulation of SC and PP fields were measured in each neuron, in counterbalanced fashion. Symbols: ***P < 0.001 vs. WT (control) and Girk2 β/β (GIRK2c).
Fear learning in CaMKIICre(+):Girk2 fl/fl mice expressing GIRK2a or GIRK2c. (A) EGFP expression in the dorsal CA1 of a CaMKIICre(+):Girk2 fl/fl mouse, 2 wk after infusion of the AAV8-CaMKIIΞ±-DIO-GIRK2a-IRES-EGFP virus. Scale bar: 500 microns. (B) Representative somato-dendritic currents (Vhold = β60 mV) evoked by baclofen (200 ΞΌM) and reversed by the GABABR antagonist CGP54626 (2 ΞΌM) in dorsal CA1 pyramidal neurons from CaMKIICre(+):Girk2 fl/fl mice, 2 wk after infusion of Cre-dependent control (con, mCherry), GIRK2a, or GIRK2c virus. Scale: 100 pA/100 s. (C) Summary of baclofen-induced currents in dorsal CA1 pyramidal neurons from CaMKIICre(+):Girk2 fl/fl mice, 2 wk after infusion of Cre-dependent control (con, mCherry), GIRK2a, or GIRK2c virus (F2,11 = 24.3, P < 0.001; n = 4β5/group). Symbols: ***P < 0.001 vs. control. (D) Contextual fear learning in untreated CaMKIICre(β):Girk2 fl/fl mice and CaMKIICre(+):Girk2 fl/fl mice, and in CaMKIICre(+):Girk2 fl/fl mice following infusion of Cre-dependent control (con, mCherry), GIRK2a, or GIRK2c virus in the dorsal CA1 (F4,55 = 14.7, P < 0.001; n = 6β23/group). Symbols: *,***P < 0.05 and 0.001, respectively, vs. Cre(β). (E) Cue fear learning in untreated CaMKIICre(β):Girk2 fl/fl mice and CaMKIICre(+):Girk2 fl/fl mice, and in CaMKIICre(+):Girk2 fl/fl mice following infusion of Cre-dependent control (con, mCherry), GIRK2a, or GIRK2c virus in the dorsal CA1 (F4,55 = 4.0, P < 0.01; n = 6β23/group). Symbols: **P < 0.01 vs. Cre(β).
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | 2023 | 36207584 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Live-cell quantitative monitoring reveals distinct, high-affinity GΞ²Ξ³ regulations of GIRK2 and GIRK1/2 channels. | Handklo-Jamal R et al. | β | 2025 | β |
| Machine learning identifies lactate metabolism biomarkers and deciphers immune infiltration landscapes in Parkinson's disease. | Lv H et al. | β | 2025 | β |
| Amyloid-Ξ² oligomers trigger sex-dependent inhibition of GIRK channel activity in hippocampal neurons in mice. | Luo H et al. | β | 2024 | β |
| Domain-selective and sex-dependent regulation of learning and memory in mice by GIRK channel activity in CA1 pyramidal neurons of the dorsal hippocampus. | Luo H et al. | β | 2024 | β |
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | Popova D et al. | β | 2023 | β |
| Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits. | Kleschevnikov AM | β | 2022 | β |
| GIRK2 Channels in Down Syndrome and Alzheimer's Disease. | Kleschevnikov A | β | 2022 | β |
| Neuronal G protein-gated K<sup>+</sup> channels. | Luo H et al. | β | 2022 | β |
| Spatial Memory Training Counteracts Hippocampal GIRK Channel Decrease in the Transgenic APP<sub>Sw,Ind</sub> J9 Alzheimer's Disease Mouse Model. | Temprano-Carazo S et al. | β | 2022 | β |
| Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology. | Weaver CD et al. | β | 2021 | β |
| Spatiotemporal Regulation of Transcript Isoform Expression in the Hippocampus. | Park J et al. | β | 2021 | β |
| GPCR-dependent biasing of GIRK channel signaling dynamics by RGS6 in mouse sinoatrial nodal cells. | Anderson A et al. | β | 2020 | β |
| The antitussive cloperastine improves breathing abnormalities in a Rett Syndrome mouse model by blocking presynaptic GIRK channels and enhancing GABA release. | Johnson CM et al. | β | 2020 | β |
| Acetylcholine release inhibits distinct excitatory inputs onto hippocampal CA1 pyramidal neurons via different cellular and network mechanisms | Goswamee P et al. | β | 2019 | β |
| Acetylcholine Release Inhibits Distinct Excitatory Inputs Onto Hippocampal CA1 Pyramidal Neurons via Different Cellular and Network Mechanisms. | Goswamee P et al. | β | 2019 | β |
| Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep. | Zou B et al. | β | 2019 | β |
| VU0810464, a non-urea G protein-gated inwardly rectifying K<sup>+</sup> (K<sub>ir</sub> 3/GIRK) channel activator, exhibits enhanced selectivity for neuronal K<sub>ir</sub> 3 channels and reduces stress-induced hyperthermia in mice. | Vo BN et al. | β | 2019 | β |
| Nociceptin/Orphanin-FQ Inhibits Gonadotropin-Releasing Hormone Neurons via G-Protein-Gated Inwardly Rectifying Potassium Channels. | Constantin S et al. | β | 2018 | β |